-
×
Dermaren Lumi Eyes
£30.80 -
×
-
×
NEXFILL Deep 1 ml Lidocaine
£30.00
Plenhyage XL Medium
£54.99 (£65.99 inc VAT)
Plenhyage XL Medium is a regenerative treatment containing 2% high molecular weight polynucleotides. It repairs, revitalises, and hydrates the skin, addressing sun damage, scars, and photoaging while promoting cell turnover and elasticity.
Includes:
1 x 2ml pre-filled syringe
2 x 30G 1/2″ needles
Free shipping
For all orders over £150
Free gift wrapping
With 100 letters custom note
Special discounts
Coupons up to £100
Expert Customer Service
8:00 - 20:00, 7 days/week

Description
Plenhyage XL Medium is a revolutionary sterile product that embodies the latest advancements in regenerative medicine. Formulated with 2% high molecular weight polynucleotides, this treatment is ideal for repairing, revitalising, and regenerating facial tissues. It effectively promotes cell turnover, improves skin elasticity, and addresses issues such as sun damage, photoaging, and scars (including acne).
The unique composition of Plenhyage XL Medium ensures enhanced hydration, free radical protection, and optimal conditions for fibroblast growth, aiding in tissue repair and revitalisation. It’s an excellent choice for individuals preparing their skin for other aesthetic treatments or seeking to rejuvenate their skin safely and effectively.
Key Features:
- Repairs, revitalises, and regenerates facial tissues
- Promotes cell turnover and fibroblast growth
- Improves skin elasticity and hydration
- Reduces cell damage from UV radiation and free radicals
- Ideal for sun-damaged skin, scars, photoaging, and acne
Treatment Areas:
- Face
- Neck
- Décolleté
Composition:
- 2% high molecular weight polynucleotides
Storage:
- Store at 2°C to 25°C.
Results typically last for up to 12 months.
Please refer to the manufacturer’s instructions before useResults typically last several months, depending on individual skin characteristics and treatment areas.
Please refer to the manufacturer’s instructions before use..
Reviews
There are no reviews yet.